BioCell
Biocell Corporation is a New Zealand biotechnology company dedicated to the process development and manufacturing of vaccines from virus and bacterial sources. They contract manufacture vaccines and sterile injectables, formulate, trial, register new products, and provide services such as packing, filling, and regulatory documentation. Their mission is to produce high-quality biological products for humans, animals, and plants, supporting the 'One Health' approach. They operate state-of-the-art GMP-approved facilities in Auckland, with a focus on innovation in vaccine manufacturing, cell therapy, fermentation technology, and RNA production platforms.
Industries
Nr. of Employees
small (1-50)
BioCell
19 Laureston Avenue, Papatoetoe, Auckland, New Zealand
Patents
Multiantivirus compound, composition and method for treatment of virus diseases
US-8722642-B2
View DetailsMultiantivirus compound, composition and method for treatment of virus diseases
US-8420617-B2
View Details
Multiantivirus compound, composition and method for treatment of virus diseases
US-8722642-B2
View DetailsMultiantivirus compound, composition and method for treatment of virus diseases
US-8420617-B2
View DetailsProducts
Protein carbonyl ELISA kit
An ELISA-based assay kit for quantitative measurement of protein carbonyls in biological samples, supplied with standards, controls, reagents, plates and instructions.
Protein carbonyl ELISA kit
An ELISA-based assay kit for quantitative measurement of protein carbonyls in biological samples, supplied with standards, controls, reagents, plates and instructions.
Services
End-to-end process development and GMP production of viral and bacterial vaccines, including seed stock management and scale-up from pilot to commercial batches.
Manufacture of sterile chemical and biological injectables in ISO-certified cleanrooms with aseptic processes, sterility assurance and GMP documentation.
Formulation and fill-finish services including automatic high-speed filling for large-scale production and manual filling for small or development batches, with labelling, packing and GMP Certificates of Compliance.
Biocontainment level 2 fermentation suites with multiple bioreactors and downstream inline centrifuges for manufacture and supply of biological antigens.
Scalable in vitro transcription services to produce custom mRNA from provided DNA sequences, with RNase/DNase controls and process parameters optimised for stability and yield.
End-to-end process development and GMP production of viral and bacterial vaccines, including seed stock management and scale-up from pilot to commercial batches.
Manufacture of sterile chemical and biological injectables in ISO-certified cleanrooms with aseptic processes, sterility assurance and GMP documentation.
Formulation and fill-finish services including automatic high-speed filling for large-scale production and manual filling for small or development batches, with labelling, packing and GMP Certificates of Compliance.
Biocontainment level 2 fermentation suites with multiple bioreactors and downstream inline centrifuges for manufacture and supply of biological antigens.
Scalable in vitro transcription services to produce custom mRNA from provided DNA sequences, with RNase/DNase controls and process parameters optimised for stability and yield.
Expertise Areas
- Vaccine manufacturing (viral and bacterial)
- Sterile injectable production and aseptic fill-finish
- Fermentation and antigen production
- Cell culture and cell-therapy processing
Key Technologies
- Cell culture biomanufacturing
- Bioreactors up to 1000 L
- Inline centrifugation for downstream processing
- Automated high-speed vial filling
News & Updates
Biocell's new vaccine filling machine is on target for completion in Germany, potentially boosting Covid-19 vaccine supply in New Zealand and globally.
The NZ government has allocated $3 million to upgrade Biocell's facilities for large-scale Covid-19 vaccine production.
Biocell has developed RapidNA, a scalable platform for high-quality RNA production, supporting Covid-19 vaccine development in New Zealand.
Biocell partners with Stabilitech to manufacture its oral Covid-19 vaccine, OraPro-COVID-19.
Biocell's RapidNA platform enables large-scale, high-quality RNA production for Covid-19 vaccines.
Professor Christine Winterbourn, director of the free radical research group at the University of Otago, was awarded the Rutherford Medal for her pioneering research on free radicals in human cells.
Biocell's new vaccine filling machine is on target for completion in Germany, potentially boosting Covid-19 vaccine supply in New Zealand and globally.
The NZ government has allocated $3 million to upgrade Biocell's facilities for large-scale Covid-19 vaccine production.
Biocell has developed RapidNA, a scalable platform for high-quality RNA production, supporting Covid-19 vaccine development in New Zealand.
Biocell partners with Stabilitech to manufacture its oral Covid-19 vaccine, OraPro-COVID-19.
Biocell's RapidNA platform enables large-scale, high-quality RNA production for Covid-19 vaccines.
Professor Christine Winterbourn, director of the free radical research group at the University of Otago, was awarded the Rutherford Medal for her pioneering research on free radicals in human cells.